FDANews
FDAnews Drug Daily Bulletin

FDA Tacks on Safety Warning to Olanzapine Labels

May 17, 2016

The FDA is adding a new warning to the label of the antipsychotic medicine olanzapine because it can cause a serious skin condition that can spread to other parts of the body.

The reaction, known as Drug Reaction with Eosinophilia and Systemic Symptoms, shows the combined symptoms of a fever with a rash and swollen lymph glands, or swelling in the face.

 

View More Stories